The goal of this section will be to discuss some of the ongoing clinical trials in pancreatic cancer, both within our lab, and in general. At this page, there is no way we will be able to discuss all the clinical trials registered in pancreatic cancer. We will start with trials affiliated with our laboratory and with Columbia University, and build from there over time.
VERY IMPORTANT DISCLAIMER!!!
Our goal here is to be objectively informative. We will NOT publish any opinions regarding which trial is "best". Such decisions are completely dependent on the circumstances of each patient, and should be approached in consultation with an oncologist. Rather, we will endeavor to present the concepts on which each trial is based, the pros and cons of design, and any associated preclinical or clinical data in a manner that is clear and straightforward.
Columbia Pancreas Center Clinical Trials:
- A PHASE Ib/ll, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MUTIPLE IMMUNOTHERAPY -BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER) Investigator Dr. Gulam Manji
- AN OPEN-LABEL, MULTICENTER PHASE Ib STUDY OF THE SAFETY AND EFFICACY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) ADMINISTERED IN COMBINATION WITH BEVACIZUMAB AND/OR OTHER TREATMENTS IN PATIENTS WITH SOLID TUMORS Investigator: Dr. Gulam Manji
For more information about clinical trials being conducted at Columbia University please visit: cancer.columbia.edu/clinical-trials/
For more information about clinical trials being conducted around the world please visit https://clinicaltrials.gov/